How Much Does Trulicity Cost in New Hampshire in 2026?

Retail Cash Price for Trulicity in New Hampshire

The manufacturer list price set by Eli Lilly for Trulicity is $931 per month in 2026, and this figure matches the average cash-pay price across New Hampshire retail pharmacies. That number applies to all four available doses (0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg), since Trulicity ships as a single-pen-per-week carton regardless of strength. Patients paying out of pocket should expect to spend roughly $11,172 per year.

Price variation between pharmacies in New Hampshire is minimal for brand-name Trulicity, because the wholesale acquisition cost is standardized by Eli Lilly. Independent pharmacies, CVS, Walgreens, and Rite Aid locations across Manchester, Nashua, Concord, and smaller towns typically price within $10 to $20 of one another for this drug. GoodRx and similar discount aggregators occasionally show prices between $880 and $950 depending on location, but these fluctuate weekly 1.

A 2019 analysis published in Diabetes Care found that GLP-1 receptor agonist list prices in the United States rose by an average of 8.5% annually between 2014 and 2019, outpacing inflation by a factor of four 2. Trulicity's list price has remained at $931 since late 2024, which represents a plateau after years of increases.

For comparison, semaglutide (Ozempic) carries a list price of approximately $935 per month and tirzepatide (Mounjaro) sits near $1,023 per month. Trulicity's price is competitive within the GLP-1 receptor agonist class, though all three drugs remain expensive without insurance or manufacturer assistance.

New Hampshire Medicaid and Trulicity Coverage

New Hampshire Medicaid does not include Trulicity on its preferred drug list for type 2 diabetes management. This means Granite Staters enrolled in Medicaid, including the state's Medicaid expansion population managed through Ambetter (Centene) and other MCOs, will not receive automatic coverage for dulaglutide.

The state's preferred alternatives for GLP-1 therapy typically include older agents or require step therapy through metformin and sulfonylureas first. Prescribers can submit a prior authorization request to the New Hampshire Department of Health and Human Services if a patient has failed preferred therapies or has a documented contraindication. Approval is not guaranteed, and the process often takes 5 to 14 business days 3.

The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite endpoint of major adverse cardiovascular events (MACE) by 12% compared to placebo over a median follow-up of 5.4 years (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) 4. This cardiovascular benefit may strengthen a prior authorization argument for patients with established atherosclerotic disease or multiple cardiovascular risk factors.

Dr. Ildiko Lingvay, an endocrinologist at UT Southwestern Medical Center, has noted: "REWIND was the first GLP-1 RA cardiovascular outcomes trial to enroll a majority of participants without established cardiovascular disease, which broadens the clinical applicability of the results."

Patients denied coverage should request a formal written denial letter, which is required for the appeals process under New Hampshire RSA 420-J:5.

Commercial Insurance Coverage in New Hampshire

Most large commercial insurers operating in New Hampshire provide some level of coverage for Trulicity, though formulary tier placement and cost-sharing vary significantly. Anthem Blue Cross Blue Shield, Harvard Pilgrim Health Care, Cigna, and Aetna all list dulaglutide on their formularies as of 2026, but typically on a non-preferred brand tier (Tier 3 or specialty tier).

Patients with Tier 3 placement should expect copays between $60 and $150 per month. Specialty tier copays or coinsurance can run $200 to $350 per fill. Prior authorization requirements are common. Insurers generally require documentation that the patient has tried and failed metformin, and some require failure of a second oral agent before approving a GLP-1 receptor agonist 5.

A practical step-by-step approach for New Hampshire patients:

1. Ask your prescriber to check your plan's formulary before writing the prescription
2. If Trulicity is non-preferred, ask whether your plan prefers a different GLP-1 RA (some plans favor Ozempic or Mounjaro)
3. Request that your prescriber submit prior authorization proactively rather than waiting for a pharmacy rejection
4. If denied, file a formal appeal citing clinical necessity and the REWIND cardiovascular data

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit as second-line therapy for patients with type 2 diabetes and established or high-risk atherosclerotic cardiovascular disease 6.

The Eli Lilly Trulicity Savings Card

Eli Lilly offers a manufacturer savings card for commercially insured patients that can reduce out-of-pocket costs to as little as $25 per monthly fill. The card is available to patients with commercial insurance and cannot be used alongside Medicare, Medicaid, Tricare, or any other federal or state government payer program.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Trulicity, must be a U.S. resident, and must be at least 18 years old. The savings card covers the difference between the patient's copay and $25, up to a maximum annual benefit. In 2026, the annual cap sits at approximately $3,600 in manufacturer-subsidized savings, enough to cover most patients for a full calendar year unless their copay exceeds $325 per fill.

New Hampshire patients can activate the card at TrulicitySavings.com or by calling Eli Lilly's patient support line. Activation takes about five minutes. The card works at any participating New Hampshire pharmacy and is presented alongside the patient's insurance card at pickup.

One point of caution: Eli Lilly periodically adjusts savings card terms. The $25 minimum copay and annual cap may change at the manufacturer's discretion, so patients should verify current terms each January 1.

Compounded Dulaglutide in New Hampshire

Compounded dulaglutide is available in New Hampshire through 503A-licensed compounding pharmacies. Under the Federal Food, Drug, and Cosmetic Act Section 503A, patient-specific compounding is permitted when a licensed prescriber writes a prescription for an individual patient and the compounding pharmacy meets all state and federal requirements 7.

New Hampshire's Board of Pharmacy regulates compounding pharmacies under RSA 318, and 503A pharmacies operating in the state must hold a valid New Hampshire pharmacy license. Compounded versions of dulaglutide are not FDA-approved and do not carry the same bioequivalence guarantees as brand-name Trulicity.

The FDA has taken an increasingly active stance toward compounded GLP-1 receptor agonists since 2024. In February 2025, the FDA issued guidance clarifying that compounders must demonstrate that the active pharmaceutical ingredient they use meets USP compendial standards and that finished preparations undergo appropriate potency and sterility testing 7.

Patients considering compounded dulaglutide should:

• Verify the pharmacy holds a current 503A license with the New Hampshire Board of Pharmacy
• Confirm the pharmacy performs third-party potency and sterility testing on each lot
• Ask for a Certificate of Analysis for the dulaglutide API used
• Understand that compounded products are not substitutable for brand-name Trulicity and may differ in concentration, excipients, or device delivery

Cost for compounded dulaglutide varies by pharmacy but is typically lower than the $931 brand-name price. Prices from New Hampshire-serving 503A pharmacies range from $150 to $450 per month depending on dose and pharmacy.

Telehealth Access to Trulicity in New Hampshire

Telehealth prescribing of Trulicity is legal in New Hampshire. The state's telemedicine statute (RSA 329:1-d) authorizes licensed physicians, nurse practitioners, and physician assistants to prescribe medications, including injectable GLP-1 receptor agonists, via audio-video telehealth visits conducted from anywhere in the state.

New Hampshire does not require an initial in-person visit before telehealth prescribing, which means patients in rural areas (Coos County, Grafton County, Carroll County) can access GLP-1 therapy without driving to Manchester or Concord. The prescriber must hold a valid New Hampshire medical license or be registered through the Interstate Medical Licensure Compact, of which New Hampshire is a member state 8.

HealthRX provides telehealth consultations with board-certified clinicians who can evaluate patients for GLP-1 receptor agonist therapy. The process involves a medical intake, lab review (HbA1c, fasting glucose, renal function), and a video consultation. If clinically appropriate, the prescriber sends the Trulicity prescription to the patient's preferred New Hampshire pharmacy.

A 2021 study in The Lancet Digital Health found that telehealth-managed type 2 diabetes patients achieved equivalent HbA1c reductions (mean difference 0.03%, 95% CI -0.09 to 0.16) compared to in-person care over 12 months 9.

Dulaglutide Clinical Profile: What You're Paying For

Dulaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, and slowing gastric emptying. The once-weekly injection offers convenience over daily injectable alternatives. Trulicity's pen device is pre-filled and does not require manual needle attachment, which reduces injection anxiety and preparation errors.

Clinical efficacy data from the AWARD trial program (nine phase III trials, collectively enrolling over 6,000 patients) showed HbA1c reductions of 0.7% to 1.6% depending on dose and comparator. The 1.5 mg dose reduced HbA1c by a mean of 1.1% in the AWARD-1 trial at 52 weeks versus 0.5% for placebo 10.

Weight loss with dulaglutide is modest compared to semaglutide 2.4 mg. In REWIND, mean body weight reduction was 2.9 kg (6.4 lb) over the trial period with dulaglutide 1.5 mg versus 1.4 kg with placebo 4. Patients seeking greater weight loss may benefit from dose escalation to 3.0 mg or 4.5 mg, which became available after the initial approval.

The 2024 ADA/EASD consensus report notes: "GLP-1 receptor agonists with demonstrated cardiovascular benefit (liraglutide, semaglutide, dulaglutide) should be prioritized in patients with type 2 diabetes and atherosclerotic cardiovascular disease, independent of baseline HbA1c" 6.

Common side effects include nausea (reported in 12% to 21% of patients in AWARD trials), diarrhea (8% to 12%), vomiting (6% to 12%), and decreased appetite. These gastrointestinal effects tend to diminish after 4 to 8 weeks and are less likely with gradual dose titration starting at 0.75 mg for the first four weeks before escalating.

Strategies to Lower Trulicity Costs in New Hampshire

Several approaches can meaningfully reduce what New Hampshire residents pay for dulaglutide:

Eli Lilly Savings Card. Commercially insured patients can pay as low as $25 per fill. This is the single most impactful cost-reduction tool for eligible patients.

Prior authorization for preferred tier placement. Some insurers will reclassify Trulicity to a lower cost-sharing tier if the prescriber documents cardiovascular risk factors and prior therapy failures. The copay difference between Tier 2 and Tier 3 can be $40 to $80 per fill.

Pharmacy benefit manager (PBM) negotiation. Patients enrolled in employer-sponsored plans can ask their HR department whether the PBM has negotiated a lower net price for Trulicity. Some large employers have carve-out arrangements that reduce cost-sharing below the plan's standard formulary tier.

503A compounding. Where clinically appropriate and under prescriber supervision, compounded dulaglutide from licensed New Hampshire pharmacies offers a lower-cost alternative. Patients and prescribers should weigh the cost savings against the absence of FDA approval for the compounded formulation.

Eli Lilly Solutions Center. Uninsured or underinsured patients may qualify for Lilly's patient assistance program, which provides Trulicity at no cost to patients who meet income thresholds (generally at or below 400% of the federal poverty level for a household).

Mail-order pharmacies. Some New Hampshire insurers offer lower copays for 90-day mail-order fills compared to 30-day retail fills. A 90-day supply through mail order can save $15 to $60 over three monthly retail fills 5.

Patients with Medicare Part D coverage face the most challenging cost picture. Medicare recipients cannot use the Eli Lilly Savings Card, and Part D plans may place Trulicity on a specialty tier with 25% to 33% coinsurance. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective January 2025) does limit total annual exposure, but patients may still pay $166 per month before reaching the cap.